February 13th 2025
The Phase II eNRGy trial showed durable antitumor activity with zenocutuzumab (Bizengri) in patients with NRG1 fusion–positive cancers, particularly non-small cell lung cancer and pancreatic cancer.
February 13th 2025
February 13th 2025
SCOPE Summit 2025: Enhancing the Patient Experience Through Site Centricity
February 12th 2025In an interview with ACT senior editor Andy Studna at SCOPE Summit, Ashley Davidson, vice president, product lead - sponsor tech strategy, Advarra, highlights the need for more site-centric approaches in study startup.
Phase III EV-302/KEYNOTE-A39 trial confirms that the combination of Padcev (enfortumab vedotin) and Keytruda (pembrolizumab) provides sustained and significant overall survival and progression-free survival benefits compared to chemotherapy in previously untreated patients with locally advanced or metastatic urothelial cancer.
SCOPE Summit 2025: Richard Young on CluePoints' Approach to Risk Detection in Clinical Trials
February 7th 2025In an interview with Applied Clinical Trials Associate Editor Don Tracy, Richard Young, chief strategy officer, CluePoints, discusses goals of the SCOPE Summit and CluePoints' evolving approach to risk detection.
Tecentriq Falls Short in Phase III Trial in Post-Surgery Triple-Negative Breast Cancer Patients
In the ALEXANDRA/IMpassion030 trial, Tecentriq (atezolizumab) added to postoperative chemotherapy was not found to improve treatment outcomes for patients with high-risk early-stage triple-negative breast cancer.
SCOPE Summit 2025: Veeva’s Drew Garty Discusses Pragmatic Clinical Trials
February 5th 2025In an interview with ACT senior editor Andy Studna at SCOPE Summit, Garty, chief technology officer, clinical data, provided his key takeaways from a panel he participated in on the growing interest around pragmatic studies.